Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis
- 9 June 2017
- journal article
- clinical trial
- Published by Wiley in American Journal of Hematology
- Vol. 92 (9) , 879-884
Abstract
Patients with relapsed/refractory Hodgkin lymphoma (RR‐HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents have impacted prognosis in general population of patients with RR‐HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR‐HL with relapse post‐ASCT. Treatment with novel agents (including brentuximab vedotin) was associated with significant improvement in median overall survival (OS) compared to patients who did not receive novel agents (85.6 vs 17.1 months;P < .001). Additional factors associated with improved OS in univariate analysis include treatment with radiation therapy post‐ASCT (34.1 vs 17.0 months;P = .015), chemosensitivity (i.e., relapsed compared to primary refractory disease; 51.8 vs 25.6 months; p = 0.013), initial response to ASCT (i.e., CR/PR compared to SD/PD; 46.1 vs 20.4 months;P = .011), and transplantation in 2010 and later compared to prior to 2010 (not reached vs 24.5 months;P = .025). The current study demonstrates markedly improved OS in RR‐HL patients treated with novel therapeutics and lends “real world” credence to the role of these agents in improving outcomes in the current era.Keywords
This publication has 23 references indexed in Scilit:
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaBlood, 2016
- Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplantLeukemia & Lymphoma, 2014
- Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantationAnnals of Oncology, 2013
- Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantLeukemia & Lymphoma, 2013
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Outcomes of Hodgkin’s Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2012
- Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centresBritish Journal of Haematology, 2011
- Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaBritish Journal of Haematology, 2009
- Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s LymphomaTransplantation and Cellular Therapy, 2006
- Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trialThe Lancet, 2002